Stati Uniti - inglese - NLM (National Library of Medicine)

caplin steriles limited - argatroban (unii: iy90u61z3s) (argatroban anhydrous - unii:ocy3u280y3) - argatroban injection is indicated for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (hit). argatroban injection is indicated as an anticoagulant in adult patients with or at risk for hit undergoing percutaneous coronary intervention (pci). argatroban is contraindicated in: - patients with major bleeding, [see warnings and precautions (5.1 )] - patients with a history of hypersensitivity to argatroban. airway, skin, and generalized hypersensitivity reactions have been reported [see adverse reactions (6.1) ] risk summary limited data from published literature and postmarketing reports do not suggest an association between argatroban and adverse fetal developmental outcomes. there are risks to the mother associated with untreated thrombosis in pregnancy and a risk of hemorrhage in the mother and fetus associated with use of anticoagulants (see clinical considerations) . in animal reproduction studies, there was no evidence of adverse developmental outcomes with in

Stati Uniti - inglese - NLM (National Library of Medicine)

caplin steriles limited - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan injection, usp is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. limitations of use: • use only if a clear diagnosis of migraine or cluster headache has been established. if a patient has no response to the first migraine attack treated with sumatriptan injection reconsider the diagnosis before sumatriptan injection is administered to treat any subsequent attacks. • sumatriptan injection is not indicated for the prevention of migraine attacks or cluster headache attacks. sumatriptan injection is contraindicated in patients with: • ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1)]. • wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2)]. • his

Stati Uniti - inglese - NLM (National Library of Medicine)

caplin steriles limited - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: • as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age • to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu • to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older. limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate have been reported [see warnings and precautions (5.4)] . the use of 10 ml cisatracurium besylate multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains ben

Stati Uniti - inglese - NLM (National Library of Medicine)

caplin steriles limited - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: otitis externa in adults and pediatric patients, 6 months and older, due to escherichia coli, pseudomonas aeruginosa and staphylococcus aureus . chronic suppurative otitis media in patients 12 years and older with perforated tympanic membranes due to proteus mirabilis, pseudomonas aeruginosa and staphylococcus aureus . acute otitis media in pediatric patients one year and older with tympanostomy tubes due to haemophilus influenzae, moraxella catarrhalis , pseudomonas aeruginosa, staphylococcus aureus and streptococcus pneumoniae . ofloxacin otic solution 0.3% is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

Stati Uniti - inglese - NLM (National Library of Medicine)

caplin steriles limited - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *efficacy for this organism was studied in fewer than 10 infections ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see warnings ).

Stati Uniti - inglese - NLM (National Library of Medicine)

medical purchasing solutions, llc - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). acute pain in adult patients ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administr

Stati Uniti - inglese - NLM (National Library of Medicine)

torrent pharmaceuticals limited - gatifloxacin anhydrous (unii: 81485y3a9a) (gatifloxacin anhydrous - unii:81485y3a9a) - gatifloxacin ophthalmic solution 0.5 % is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: •    aerobic gram-positive bacteria:             staphylococcus aureus             staphylococcus epidermidis             streptococcus mitis group *             streptococcus oralis*             streptococcus pneumoniae •    aerobic gram-negative bacteria:             haemophilus influenzae *efficacy for these organisms were studied in fewer than 10 infections. gatifloxacin ophthalmic solution 0.5% is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication [see warnings and precautions ( 5.1)]. risk summary there are no available data on the use of gatifloxacin ophthalmic solution 0.5% in pregnant women to inform a drug-associated risk. administration of oral gatifloxacin to pregnant rats and rabbits throughout

Emirati Arabi Uniti - inglese - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

25 glass vials (2 ml) -

Emirati Arabi Uniti - inglese - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

25 glass vials (1 ml) -

Emirati Arabi Uniti - inglese - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

10's (10 ml x 10 multiple dose glass vials) -